Ann: Extension for Voluntary Suspension, page-240

Hi barra, fair call on the lawyer costs etc, I was referring to the bulk costs of the R&D for the vacc.
Admedus did receive two lots of 500 grand (?) from SB, that should have covered those cash outflows plus funds over.

Sentiment was as well as could be expected at CodeRed launch, and alright up til the failed 30 cent CR a while back.

Not sure your ref to my cliches, I have no contact with management barra, rely on ASX announcements for the bottom line.

CodeRed should have been kick off for Admedus, it was not for whatever reasons, imo.

Ref: another poster: I do not expect WP to ‘know’ everything, but I do have a reasonably expectancy that he should know ‘most’ of what needs to be known, you seem to forget that WP made many claims to support our beliefs that everything was well in hand, fact, right up to the end.
It is concerning that the team at Admedus totally failed to have a handle on this, the lot of them with all their experience, if that is ‘normal’ why would anybody invest in a spec stock?

Shame not as forgiving on another stock.

Not about the blame game now but the future and the impact on RIs, let’s agree to disagree on the ‘blame’.

Lets keep to facts, as much as we can and forgo the ‘infighting’.